Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously overlooked brain circuit that helps explain how prior adversity can make the brain more reactive to future stress.

The study, published Sept. 30 in Nature and conducted in mice, identifies a small, deep brain structure called the anterior hypothalamic nucleus (AHN) as a critical hub that scales the brain’s response to threatening events. The research team found that dialing its activity up or down directly altered how strongly the animals responded to stress.

“Why do some people develop debilitating mental health conditions in response to stress while others do not? One known risk factor for heightened stress sensitivity is a history of prior stress, such as early childhood adversity or adult traumatic stress. However, at a biological level, we still do not fully understand why this is the case,” says Zachary Pennington, Ph.D., lead author of the paper, who conducted the research as a postdoctoral fellow in the Cai Lab at Mount Sinai and is now an assistant professor of psychology and a member of the Djavad Mowafaghian Centre for Brain Health at the University of British Columbia.

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis. The results are striking because existing MS treatments are designed to reduce future inflammatory attacks, not restore neurological function already lost.

The research is published in the journal Science Translational Medicine.

The drug, Kamuvudine K-9, is a derivative of HIVdrugs already approved for use in people. It was developed by Jayakrishna Ambati, MD, founding director of UVA’s Center for Advanced Vision Science and the DuPont Guerry III Professor in the UVA School of Medicine’s Department of Ophthalmology.

Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more.